《滬深兩市》上證半日微跌 深成創板跌1%-1.4% 寧德時代回吐3.7%
內地疫情反覆,昨日(17日)新增本土確診病例2,388例,新增本土無症狀感染者1,742例。人民銀行今日(18日)進行300億元人民幣(下同)7天期逆回購操作,單日淨投放200億元。中美兩國元首今晚通電話 商討中美關係及俄烏等問題。人民幣兌美元中間價今下調19點。上證深成今早低開後偏軟,深成及創板跌幅較大。
上證半日反覆跌7點或0.2%,收報3,208點;深成指跌116點或1%,收報12,173點;創業板指數半日跌37點或1.4%,收報2,673點,成交1,405億元。上證深成半日成交分別為2,349億元及3,298億元。
中資金融股表現偏好,工行(601398.SH)及建行(601939.SH)分別升0.2%及0.7%。中國平安(601318.SH)去年純利跌29%至1,016.18億元遜預期,股價靠穩升0.2%。
華海藥業(600521.SH)、普洛藥業(000739.SZ)、復星醫藥(600196.SH)、九洲藥業(603456.SH)獲允許生產輝瑞新冠口服藥Paxlovid成分之一奈瑪特韋(nirmatrelvir)原料藥或製劑。相關股份個別發展,復星醫藥(600196.SH)升2.6%,其餘三隻藥股跌3.2%-4%。
工信部發布2022年汽車標準化工作要點提出,研究發布汽車芯片標準體系,啟動電動車動力蓄電池安全標準修訂工作。惟相關龍頭芯片鋰電池股走疲,贛鋒鋰業(002460.SZ)及隆基股份(601012.SH)分別跌1.1%及1.6%。寧德時代(300750.SZ)回吐3.7%。比亞迪(002594.SZ)亦跌0.6%。
國際油價反彈,中石油(601857.HK)升1.8%。
白酒股回軟,龍頭股貴州茅台(600519.SH)及五糧液(000858.SZ)分別跌1.4%及1.3%。(ta/k) ~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.